PhenoTech
Philadelphia
About PhenoTech
PhenoTech a biotechnology company, engages in the discovery, development, and commercialization of reagents for diagnostic use in blood banks. The company offers blood diagnostic reagents, such as Nanoscale Emissive Antibody-complexes for Typing reagents for pre-transfusion testing. It also provides therapeutic agents, including a series of human-like monoclonal antibodies for treatment of Idiopathic Thrombocytopenic Purpura, an autoimmune disorder in the field of hematology; and anti-platelet agents, such as Infusable gpIIb/IIIa antagonist agents that are used after acute myocardial infarction, as well as in patients undergoing balloon angioplasty or stent placement in order to prevent cardiac ischemic complications.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Seed
- Last round: Seed (Mar 2004)
- Website: phenotech.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/phenotech-433808 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.